Keiser Jennifer, Utzinger Jürg
Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, PO Box, CH-4002 Basel, Switzerland.
JAMA. 2008 Apr 23;299(16):1937-48. doi: 10.1001/jama.299.16.1937.
More than a quarter of the human population is likely infected with soil-transmitted helminths (Ascaris lumbricoides, hookworm, and Trichuris trichiura) in highly endemic areas. Preventive chemotherapy is the mainstay of control, but only 4 drugs are available: albendazole, mebendazole, levamisole, and pyrantel pamoate.
To assess the efficacy of single-dose oral albendazole, mebendazole, levamisole, and pyrantel pamoate against A lumbricoides, hookworm, and T trichiura infections.
A systematic search of PubMed, ISI Web of Science, ScienceDirect, the World Health Organization library database, and the Cochrane Central Register of Controlled Trials (1960 to August 2007).
From 168 studies, 20 randomized controlled trials were included.
Information on study year and country, sample size, age of study population, mean infection intensity before treatment, diagnostic method used, time between evaluations before and after treatment, cure rate (the percentage of individuals who became helminth egg negative following treatment with an anthelminthic drug), egg reduction rate, adverse events, and trial quality was extracted. Relative risk, including a 95% confidence interval (CI), was used to measure the effect of the drugs on the risk of infection prevalence with a random-effects model.
Single-dose oral albendazole, mebendazole, and pyrantel pamoate for infection with A lumbricoides resulted in cure rates of 88% (95% CI, 79%-93%; 557 patients), 95% (95% CI, 91%-97%; 309 patients), and 88% (95% CI, 79%-93%; 131 patients), respectively. Cure rates for infection with T trichiura following treatment with single-dose oral albendazole and mebendazole were 28% (95% CI, 13%-39%; 735 patients) and 36% (95% CI, 16%-51%; 685 patients), respectively. The efficacy of single-dose oral albendazole, mebendazole, and pyrantel pamoate against hookworm infections was 72% (95% CI, 59%-81%; 742 patients), 15% (95% CI, 1%-27%; 853 patients), and 31% (95% CI, 19%-42%; 152 patients), respectively. No pooled relative risks could be calculated for pyrantel pamoate against T trichiura and levamisole for any of the parasites investigated.
Single-dose oral albendazole, mebendazole, and pyrantel pamoate show high cure rates against A lumbricoides. For hookworm infection, albendazole was more efficacious than mebendazole and pyrantel pamoate. Treatment of T trichiura with single oral doses of current anthelminthics is unsatisfactory. New anthelminthics are urgently needed.
在高度流行地区,超过四分之一的人口可能感染土源性蠕虫(蛔虫、钩虫和鞭虫)。预防性化疗是控制的主要手段,但仅有4种药物可用:阿苯达唑、甲苯达唑、左旋咪唑和噻嘧啶。
评估单剂量口服阿苯达唑、甲苯达唑、左旋咪唑和噻嘧啶治疗蛔虫、钩虫和鞭虫感染的疗效。
对PubMed、科学引文索引(ISI)科学网、ScienceDirect、世界卫生组织图书馆数据库以及Cochrane系统评价数据库(1960年至2007年8月)进行系统检索。
从168项研究中纳入了20项随机对照试验。
提取有关研究年份和国家、样本量、研究人群年龄、治疗前平均感染强度、所用诊断方法、治疗前后评估的时间间隔、治愈率(使用驱虫药物治疗后蛔虫卵转阴的个体百分比)、虫卵减少率、不良事件和试验质量的信息。采用随机效应模型,用相对危险度(包括95%置信区间)来衡量药物对感染流行风险的影响。
单剂量口服阿苯达唑、甲苯达唑和噻嘧啶治疗蛔虫感染的治愈率分别为88%(95%置信区间,79% - 93%;557例患者)、95%(95%置信区间,91% - 97%;309例患者)和88%(95%置信区间,79% - 93%;131例患者)。单剂量口服阿苯达唑和甲苯达唑治疗鞭虫感染的治愈率分别为28%(95%置信区间,13% - 39%;735例患者)和36%(95%置信区间,16% - 51%;685例患者)。单剂量口服阿苯达唑、甲苯达唑和噻嘧啶治疗钩虫感染的疗效分别为72%(95%置信区间,59% - 81%;742例患者)、15%(95%置信区间,1% - 27%;853例患者)和31%(95%置信区间,19% - 42%;152例患者)。对于噻嘧啶治疗鞭虫感染以及左旋咪唑治疗任何一种所研究的寄生虫感染,无法计算合并相对危险度。
单剂量口服阿苯达唑、甲苯达唑和噻嘧啶对蛔虫感染显示出高治愈率。对于钩虫感染,阿苯达唑比甲苯达唑和噻嘧啶更有效。目前使用单剂量口服驱虫药治疗鞭虫感染效果不理想。迫切需要新的驱虫药。